Annals of Surgery · 1994 · 59 citations · 16 references
MedicinePharmacologyPharmacotherapyImmunopharmacologyTransplant ImmunologyTransplant SurgeryAllograft RejectionImmunosuppressive TherapyMtor Inhibitor TherapyTransplant ImmunopharmacologyTransplant PharmacologyTransplant RejectionAllograft Survival AssessmentCombination Immunosuppressive RegimensGraft Survival EnhancementImmunosuppression In Limbal AllograftImmunosuppression RegimensImmunosuppressive CompoundsImmunosuppressive Drug TherapyTransplantation
OBJECTIVE: Graft rejection and the toxicity of current immunosuppressive regimens preclude the application of microsurgical advances to transplantation of limbs or other nonessential parts. If limb transplantation is to become a clinical reality, newer, safer, more effective immunosuppressive agents are needed. SUMMARY BACKGROUND DATA: Rapamycin (RPM) and FK 506 are fungal macrolide antibiotics with effective immunosuppressive properties demonstrated in several animal models. RPM is more potent and effective than is FK 506 in rat cardiac allografts and has demonstrated synergy with cyclosporine (CsA) in limb allograft models. METHODS: An orthotopic rat hind limb allograft model (Brown-Norway [RT-1n] to Lewis [RT-1(1)] rats was used. RPM (doses, 3.0, 4.5, and 6.0 mg/kg/day) was administered intraperitoneally on postoperative days 1 to 14. FK 506 (6 mg/kg/day) was administered orally on postoperative 1 to 14 and 1 to 90 and at rejection onset (10 mg/kg/day for salvage). CsA with RPM (postoperative days 1 to 14) was used to assess synergy, with CsA alone serving as the control. Other controls included untreated and placebo-treated allografted animals. The permutation test and Mann-Whitney test were applied to the data. RESULTS: The mean survival times were assessed as follows: (1) control (placebo, untreated), 5 days; (2) RPM groups, 9.5, 10.6, and 8.7 days; (3) 14-day FK 506, 28 days; (4) 90-day FK 506, > 90 days; (5) CsA, 17.3 days; and (6) CsA with RPM, 19.3 days. FK 506 significantly prolonged graft survival compared with RPM (Permutation Test, p < 0.001 and Mann-Whitney Test, p < 0.05). FK 506 salvage reversed early rejection. High-dose RPM produced significant toxicity. Synergy between CsA and RPM was not demonstrated. CONCLUSIONS: FK 506 prolongs allograft survival, reverses early rejection, and prevents rejection without clinical toxicity when given continually. RPM does not prevent rejection in this model and produces significant toxicity at high doses. FK 506 may be a first step in making limb transplantation a clinical reality in reconstructive surgery.
16
B A Reitz, J. Wallwork, Sharon A. Hunt et al. · New England Journal of Medicine · 1982 · 848 citations
Medicine, Cardiology, Surgery +14
LIMB ALLOGRAFTS IN RATS IMMUNOSUPPRESSED WITH FK506
K Arai, Takao Hotokebuchi, Hisaaki Miyahara et al. · Transplantation · 1989 · 90 citations
The Use of Cyclosporin A in clinical Organ Grafting
R. Y. CALINE, David J. White · Annals of Surgery · 1982 · 85 citations · Full text
Medicine, Pharmacotherapy, Surgery +17
Limb Allografts in Rats Immunosuppressed with Cyclosporin A
W. Fritz, William M. Swartz, Steven Rose et al. · Annals of Surgery · 1984 · 79 citations
Life Sciences, Immunology, Surgery +17